BBH
VanEck Biotech ETF
Price Chart
Latest Quote
$249.80
+4.07 (+1.66%)
Current Price
| Previous Close | $245.73 |
| Open | $246.34 |
| Day High | $249.80 |
| Day Low | $243.56 |
| Volume | 6,408 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.39% |
| Net Assets | $487.74M |
| Expense Ratio | 0.35% |
| Category | Health |
| Fund Family | VanEck |
| Net Asset Value | $247.16 |
| Premium/Discount | 1.07% |
| Quarterly Dividend Yield | 0.39% |
| P/E Ratio | 29.46 |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $242.33 |
| SMA50 | $239.77 |
| SMA200 | $205.73 |
| RSI | 62.64 |
| ATR | 5.0650 |
| Rel Volume | 0.55 |
Performance History
| Week | +0.41% |
| Month | +1.82% |
| Quarter | +19.73% |
| 6 Months | +35.88% |
| YTD | +31.31% |
| Year | +41.43% |
| 3 Years | +69.50% |
| 5 Years | +30.21% |
| 10 Years | +150.42% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $249.80 | 6,500 |
| 2026-10-26 | $247.39 | 12,800 |
| 2026-10-23 | $246.57 | 4,900 |
| 2026-10-22 | $248.41 | 17,500 |
| 2026-10-21 | $250.46 | 11,900 |
| 2026-10-20 | $248.78 | 13,300 |
| 2026-10-19 | $241.14 | 18,900 |
| 2026-10-16 | $241.36 | 14,500 |
| 2026-10-15 | $246.49 | 14,200 |
| 2026-10-14 | $241.07 | 10,700 |
| 2026-10-13 | $235.92 | 6,100 |
| 2026-10-12 | $239.22 | 10,200 |
| 2026-10-09 | $240.47 | 10,900 |
| 2026-10-08 | $234.03 | 15,800 |
| 2026-10-07 | $237.87 | 8,200 |
| 2026-10-06 | $236.30 | 16,000 |
| 2026-10-05 | $240.53 | 9,400 |
| 2026-10-02 | $237.45 | 11,600 |
| 2026-10-01 | $238.74 | 14,000 |
| 2026-09-30 | $244.58 | 6,900 |
| 2026-09-29 | $245.64 | 13,100 |
| 2026-09-28 | $245.34 | 10,200 |
About VanEck Biotech ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
đ° Latest News
No news articles available at the moment. Check back later for updates on BBH.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.